News

- 16 NOV 2017
- 0
British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities
PharmaCyte Issues Corporate Overview and History LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is providing a summary overview, corporate history and status report
Read more →
- Posted in
- News
- 03 NOV 2017
- 0
PharmaCyte Biotech Releases Shareholder Call Playback Information
LAGUNA HILLS, CA November 3, 2016 – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder call, which was held on November 1, 2017, by the Chief Executive
Read more →
- Posted in
- News
- 29 OCT 2017
- 0
PharmaCyte Biotech Update on Shareholder Call
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, will update shareholders on PharmaCyte’s clinical program for pancreatic
Read more →
- Posted in
- News
- 20 OCT 2017
- 0
PharmaCyte Biotech to Hold Shareholder Call
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder call on Wednesday, November 1, 2017, commencing at 4:30 p.m. EDT.
Read more →
- Posted in
- News
- 17 OCT 2017
- 0
PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has identified an organism whose genome contains the genetic code for production
Read more →
- Posted in
- News
- 10 OCT 2017
- 0
PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr. Raymond C.F. Tong to its Board of Directors. Dr. Tong serves as Chief Executive Officer of Harmony Medical Inc.,
Read more →
- Posted in
- News
- 13 SEP 2017
- 0
PharmaCyte Biotech Appoints Alan Morell of Creative Management Partners as Strategic Advisor
LAGUNA HILLS, CA, September 13, 2017 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Alan Morell, the Chairman and Chief Executive Officer
Read more →
- Posted in
- News
- 06 SEP 2017
- 0
PharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership
LAGUNA HILLS, CA, September 6, 2017 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has reached an agreement with Austrianova to restructure certain agreements between them pursuant
Read more →
- Posted in
- News
- 26 JUL 2017
- 0
PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer
LAGUNA HILLS, Calif., July 26, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Linda S. Sher, M.D. as the company’s Chief Medical Officer. Dr. Sher is a Professor of
Read more →
- Posted in
- News
- 10 JUL 2017
- 0
PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors
LAGUNA HILLS, Calif., July 10, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr. Michael M. Abecassis to its Board of Directors. Dr. Abecassis is a renowned transplantation surgeon
Read more →
- Posted in
- News

British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities

PharmaCyte Biotech Releases Shareholder Call Playback Information

PharmaCyte Biotech Update on Shareholder Call

PharmaCyte Biotech to Hold Shareholder Call

PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer

PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors

PharmaCyte Biotech Appoints Alan Morell of Creative Management Partners as Strategic Advisor

PharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership

PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer

PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors

Contact Us

Latest News

Subscribe to Our Mailing List